PHARMACOGENOMICS-GUIDED DRUG THERAPY FOR HYPERTENSION

Objective: The hypertension control rate is only 16.8% in China, and superior reasonable treatment is contributive to improve the rate. This study is aimed to evaluate whether pharmacogenomics-guided drug therapy is superior to conventional therapy in lowering blood pressure. Design and method: DNA samples were collected from 93 hypertensive patients. All patients entered a 4-week conventional treatment period, and then entered a 4-week pharmacogenomics-guided drug therapy period (the antihypertensive regimen was adjusted according to the pharmacogenomic report). The hypertension control rate and reduction of blood pressure (BP) were analyzed. High-throughput targeted sequencing panel was designed to detect efficacy and adverse-related genes of 24 commonly used antihypertensive drugs (5 types) and 52 gene loci were analyzed related to drug Efficacy (E): “E-”, “E”, “E+”, Tolerance (T): “T-”, “T”, “T+” and Metabolic (M): “M-”, “M”, “M+”. Clinical drug administration was guided according to relevant judgement results. Results: Compared with the conventional therapy group, the hypertension control rate of office and home blood pressure in the precise treatment group increased by 14.75% and 25.81%, respectively. The reduction of BP in the precise treatment group was greater than conventional therapy group ( Table and Figure). Conclusions: Compared with conventional therapy, the pharmacogenomics-guided drug therapy can control blood pressure more effectively. Table. Comparison of Reduction in Office Systolic Blood Pressure (SBP)and Home SBP between the Precise Treatment Group and the Conventional Therapy Group Figure: Comparison of Reduction in Office SBP and Home SBP between the Precise Treatment Group and the Conventional Therapy Group